Emerging therapies for small cell lung cancer
S Yang, Z Zhang, Q Wang - Journal of hematology & oncology, 2019 - Springer
Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …
Emerging strategies for the treatment of small cell lung cancer: a review
WJ Petty, L Paz-Ares - JAMA oncology, 2023 - jamanetwork.com
Importance Small cell lung cancer (SCLC) is an aggressive disease that is characterized by
rapid growth and the early development of metastases. Patients typically respond to initial …
rapid growth and the early development of metastases. Patients typically respond to initial …
Treatment advances in small cell lung cancer (SCLC)
SN Waqar, D Morgensztern - Pharmacology & therapeutics, 2017 - Elsevier
Small cell lung cancer (SCLC) is an aggressive tumor characterized by rapid doubling time
and high propensity for early development of disseminated disease. Although most patients …
and high propensity for early development of disseminated disease. Although most patients …
Evolving role of immunotherapy in small cell lung cancer
ED Barrows, MJ Blackburn, SV Liu - Seminars in Cancer Biology, 2022 - Elsevier
Small cell lung cancer (SCLC) is a highly lethal subtype of lung cancer with a particularly
poor prognosis. For decades, the best available systemic therapy was platinum plus …
poor prognosis. For decades, the best available systemic therapy was platinum plus …
[HTML][HTML] Novel therapies in small cell lung cancer
H Mamdani, R Induru, SI Jalal - Translational lung cancer research, 2015 - ncbi.nlm.nih.gov
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the lung with a
tendency to metastasize widely early in the course of the disease. The VA staging system …
tendency to metastasize widely early in the course of the disease. The VA staging system …
Update 2021: management of small cell lung cancer
S Tariq, SY Kim, J Monteiro de Oliveira Novaes… - Lung, 2021 - Springer
Background Accounting for 14% of lung cancer, small cell lung cancer (SCLC) is a highly
aggressive neuroendocrine malignancy with rapid proliferation, early spread, and poor …
aggressive neuroendocrine malignancy with rapid proliferation, early spread, and poor …
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC)(2019)
Small-cell lung cancer (SCLC) accounts for 15% of lung cancers. Only one-third of patients
are diagnosed at limited stage. The median survival remains to be around 15–20 months …
are diagnosed at limited stage. The median survival remains to be around 15–20 months …
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
J Trigo, V Subbiah, B Besse, V Moreno, R López… - The lancet …, 2020 - thelancet.com
Background Few options exist for treatment of patients with small-cell lung cancer (SCLC)
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …
after failure of first-line therapy. Lurbinectedin is a selective inhibitor of oncogenic …
[HTML][HTML] Small cell lung cancer: a slightly less orphan disease after immunotherapy
Highlights•ICIs have shifted the treatment paradigm to improve overall survival in advanced
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …
SCLC.•The magnitude of immune-chemotherapy strategy is still modest. The …
New insights into small‐cell lung cancer development and therapy
Y Wang, S Zou, Z Zhao, P Liu, C Ke… - Cell Biology …, 2020 - Wiley Online Library
Small‐cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases;
however, it is characterized by easy relapse and low survival rate, leading to one of the most …
however, it is characterized by easy relapse and low survival rate, leading to one of the most …